UroGen Pharma URGN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$153.49M-21.0% | -$126.87M-24.1% | -$102.24M+6.9% | -$109.78M+0.9% | ||
| $347K-11.3% | $391K-51.5% | $807K-5.2% | $851K+5.8% | ||
| $11.96M-8.8% | $13.11M+40.3% | $9.34M-11.7% | $10.58M-54.2% | ||
| —— | —— | —— | $987K— | ||
| $7.24M+104% | $3.55M— | —— | —— | ||
| $286K— | —— | —— | $281K— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$702K-155% | $1.27M— | ||
| -$202K-201% | $200K— | $0— | —— | ||
| $2.1M+146% | $857K-5.1% | $903K+1.1% | $893K-5.2% | ||
| —— | -$1.03M-4.8% | -$987K+12.3% | -$1.13M— | ||
| —— | —— | $1.01M-42.2% | $1.75M— | ||
| -$162.44M-67.9% | -$96.77M-26.7% | -$76.38M+12.8% | -$87.56M-3.1% | ||
| $289K-2.0% | $295K+52.1% | $194K-23.6% | $254K-66.2% | ||
| $139.25M+29.3% | $107.71M+119% | $49.07M-23.8% | $64.41M— | ||
| $61.56M— | —— | -$953K— | —— | ||
| —— | $24.49M— | $0— | —— | ||
| $39.8M-73.7% | $151.17M+124% | $67.36M— | $0— | ||
| $1.86M— | $0— | —— | —— | ||
| $39.92M-79.5% | $194.62M+66.4% | $116.93M+20.3% | $97.21M— | ||
| —— | —— | —— | —— | ||
| $1.88M-35.1% | $2.89M+169% | $1.08M+116% | $498K+202% | ||
| —— | —— | $1.01M-42.2% | $1.75M— | ||
| —— | —— | —— | —— | ||
| —— | -$1.03M-4.8% | -$987K+12.3% | -$1.13M— | ||
| -$202K-201% | $200K— | $0— | —— | ||
| —— | -$1.44M-75.1% | -$820K-123% | $3.63M— | ||
| $2.1M+146% | $857K-5.1% | $903K+1.1% | $893K-5.2% | ||
| $139.25M+29.3% | $107.71M+119% | $49.07M-23.8% | $64.41M+18.7% | ||
| $1.86M— | $0— | —— | —— | ||
| $2.87M-81.0% | $15.08M+31.1% | $11.5M-17.9% | $14.01M-5.7% | ||
| —— | —— | —— | —— | ||
| —— | -$1.03M-4.8% | -$987K+12.3% | -$1.13M— | ||
| $112K-81.2% | $597K+239% | $176K0.0% | $176K+40.8% | ||
| —— | $0— | —— | —— | ||
| $7.43M+220% | $2.32M— | —— | $2.17M— | ||
| —— | $0— | —— | —— | ||
| -$162.73M-67.7% | -$97.06M-26.8% | -$76.57M+12.8% | -$87.81M-2.5% | ||
| -$162.73M-67.7% | -$97.06M-26.8% | -$76.57M+12.8% | -$87.81M-2.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does UroGen Pharma generate?
- UroGen Pharma (URGN) generated -$165.7M in operating cash flow over the trailing twelve months.
- What is UroGen Pharma's free cash flow?
- After $299.0K of capital expenditures, UroGen Pharma's free cash flow was -$166.0M over the trailing twelve months, down 54.6% year over year.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
